1155PPhase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers. (23rd October 2018) - Tsimberidou, A-M; Ma, H; Stewart, C; Schoor, O; Maurer, D; Mendrzyk, R; Satelli, A; Fritsche, J; Stephens, G; Mohamed, A; Hwu, P; Yee, C; et al.